ABSTRACT. Female reproductive organs are mainly regulated by estrogen and progesterone. Specifically, the uterus, vagina and mammary gland show organ-specific mitosis and morphological changes during proliferative events, such as estrous cycle, gestation and lactation. The mechanism underlying these organ-specific estrogen-dependent events is still unknown. We examined, therefore, global gene expression in the mature uterus, vagina and mammary gland of ovariectomized adult mice 6 hr after an injection of 5 µg/kg 17β-estradiol (E 2 ) using a microarray method in order to identify primary E 2 -responsive genes. Half of the E 2 up-regulated genes in the uterus were similar to those in the vagina. E 2 up-regulated the expression of Insulin-like growth factor 1 (Igf-1) genes in the uterus and vagina. In the vagina, E 2 up-regulated the expression of IGF binding proteins (Igfbp2 and Igfbp5). In the mammary gland, unlike the uterus and vagina, no gene showed altered expression 6 hr after the E 2 exposure. These results suggest that expression of Igf-1 and morphogenesis genes is regulated by E 2 in an organ-specific manner, and it is supported by the results of BrdU labeling showing E 2 -induced mitosis in the uterus and vagina except the mammary gland. The differences in organ specificity in response to E 2 may be attributed by differences in gene expression regulated by E 2 in female reproductive organs. The candidate estrogen-responsive genes in the uterus and vagina identified by profiling provide an important foundation understanding functional mechanisms of estrogen regulating morphogenesis and maintenance of each reproductive organ.
Female reproductive organs vary their morphology during reproductive events, such as differentiation, development, estrous cycle, gestation and lactation. Estrogen is known to have differential developmental effects widely on the uterus, vagina, mammary gland, bone, liver, thymus and brain as its target organs. Although the proliferation of uterine and vaginal epithelia, and ductal elongation of mammary gland in mice could be regulated by estrogen alone [20] , the mammary gland requires progesterone and prolactin in addition to estrogen to complete the architecture [12, 17, 33] . Ovariectomy and termination of weaning induce apoptosis in epithelial cells in the uterus, vagina and mammary gland [19, 30] . These estrogen target organs are controlled by estrogen receptors (ERα and ERβ) in the epithelial and stromal cells [9, 21, 24] . It is known, moreover, that growth factor(s) from the stroma are involved in epithelial proliferation of these organs [2, 6, 9] . An increase of epithelial and stromal cells in the uterus and vagina is mediated through Insulin-like growth factor I (IGF-1) and Epidermal growth factor (EGF) [3, 6, 14, 18] . Prolactin also induces expression of Igf-2 mRNA in the developing mammary gland [13] .
Tamoxifen, a selective ER modulator (SERM), acts as an estrogen agonist in the uterus and vagina, but acts as an estrogen antagonist in the mammary gland [22, 32] . The ligand-dependent effect on the mammary gland supports the idea of tissue specificity of gene expression by estrogen. Profiling of estrogen-regulated gene expression is reported recently in the estrogen target cells, tissues and organs [10, [34] [35] [36] . However, any comparisons of gene expression in the estrogen target organs have not not been reported. Gene expression reached a maximum 6 hr after E 2 administration in the uterus of ovariectomized adult mice without any histological changes [34] . Thus, we examined global gene expression 6 hr after a single injection of E 2 in order to identify early estrogen-responsive genes in the uterus vagina and mammary gland as the estrogen target organs in ovariectomized adult mice.
MATERIALS AND METHODS
Animals: C57BL/6J mice (CLEA, Tokyo, Japan) at 2 months of age, 20-23 g body weight, were used for mating. Mice were maintained under 12 hr light/12 hr dark at 23-25°C, fed with a commercial diet (CE-2, CLEA, Tokyo, Japan) and provided tap water ad libitum. All experiments and animal husbandry protocols were approved by the animal care committee of National Institutes of Natural Sciences.
Treatments: 17β-Estradiol (E 2 , Sigma, St. Louis, MO) was dissolved in sesame oil. Sixty-day-old mice were ovariectomized and injected with 5 µg E 2 /kg body weight after a 10-day recovery period to ensure that endogenous E 2 levels were reduced. Six hr after E 2 injection, 4 mice were killed by decapitation and the uteri, vaginae and mammary glands were collected. Four mice injected with oil vehicle only were used as controls. The tissues were pooled for DNA microarray analysis and the analyses were done on two independent experiments. Two other groups of 4 ovariectomized mice were likewise given E 2 or oil and killed 24 hr after the injection for bromodeoxyuridine (BrdU)-labeling study.
DNA microarray analysis: Total RNA was extracted from tissues (4 mice each) 6 hr after a single injection of 5 µg E 2 /kg b.w. or the oil vehicle alone. Ten µg of total RNA were used to synthesize cDNA, which was then used to generate biotinylated cRNA. The cRNA was hybridized to murine U74A version 2 GeneChip expression arrays (Affymetrix, Applied Biosystems (APB), Tokyo, Japan) as described [34] . Total RNA was extracted using TRIzol reagent (Invitrogen, Tokyo, Japan) and purified with an RNeasy total RNA purification kit (Qiagen, Tokyo, Japan).
Ten µg of total RNA were converted into double stranded cDNA using the Superscript Choice System (Invitrogen) with a T7-(dT) 24 primer (APB). Biotin-labeled cRNA was synthesized using the ENZO BioArray High Yield RNA transcript labeling kit (APB). The cRNA was purified by RNeasy (Qiagen). The purified cRNA was fragmented with fragmentation buffer (40 mM Tris, 100 mM K-acetate and 30 mM Mg-acetate) at 94°C for 35 min. Fragmented cRNA was mixed with hybridization buffer containing 100 mM MES [2-(N-morpholino)ethanesulfonic acid], 1 M NaCl, 20 mM EDTA, 0.01% Tween 20 and control oligonucleotides. The quality of cRNA was first assessed by analysis with Test 2 array (Affymetrix). cRNA was hybridized to Murine U74A version 2 GeneChip Expression Arrays (Affymetrix) for 16 hr at 45°C. All preparations were performed following manufacturer's instructions. Arrays were washed and stained with streptavidin-phycoerytherin, and scanned with an Argon-ion Laser Confocal Scanner (APB). Microarray analysis was performed twice on independent samples [34] and these raw data were loaded into NCBIs Gene Expression Omnibus as the dataset GSM159919-GSM159930 (GEO, http://www.ncbi.nlm.nih.gov/geo/). The putative target genes were validated by quantitative RT-PCR (QRT-PCR).
Statistical analysis: Signals in 2 experiments were detected using the robust multichip average (RMA) algorithms, and normalized using Genespring (Silicon Genetics, Redwoods City, CA). Expressed genes more than 40% raw signal of average raw signals in all genes on chip were selected as detected genes for next analysis. Selected genes showing more than 2-fold alterations by E 2 as compared to the tissue-matched oil controls were analyzed further using Genespring software.
Quantitative RT-PCR: One µg total RNA was reverse transcribed using Super Script II reverse transcriptase (Invitrogen) and random primers at 42°C for 50 min. PCR was performed using PE Prism 5,700 Sequence Detection System (PE Biosystems, Tokyo, Japan) with SYBR Green I dye (Molecular Probes, Eugene, OR) and primers selected by Primer Express ver 1.0 (APB). Primer sets are described in Table 1 .
PCR amplification was performed for 2 min at 50°C, for 10 min at 95°C and continued to 40 cycles at 95°C for 15 sec and at 60°C for 1 min. Data were normalized to ribosomal protein 28S RNA using delta Ct method for each primer set. The ratio was calculated as compared with oil controls of uterus.
BrdU-Labeling and Immunostaining: A single injection of 200 mg BrdU (Roche, Grenzacherstrasse, Switzerland)/ kg b.w. was given to mice (4 mice each) 1 hr before sacrifice. Uterus, vagina and mammary gland were fixed with neutral-buffered 10% formalin, embedded in paraffin and sectioned at 6 µm. Sections were dipped in PBS and endogenous peroxidase activity was blocked with 3% H 2 O 2 in methanol for 30 min. After washing in 0.5% Tween 20 in PBS twice, sections were dipped in 2N HCl for 20 min, then, neutralized sections borate buffer (0.1 M NaB 4 O 7 , pH 8.5) twice. After Tween/PBS washing, sections were dipped in 1% BSA/PBS for 20 min. Then, sections were incubated with 1:20 anti-BrdU (Roche). Sections detected with diaminobenzidine staining were analyzed. The BrdU labeling index (%) was estimated by counting BrdU positive cells in 2,000-3,000 epithelial and 10,000-20,000 stromal cells in the uterus and vagina, and in 300-500 epithelial or stromal cells in the mammary glands.
RESULTS
Gene expression in the uterus, vagina and mammary gland exposed to E 2 : Approximately 12,400 genes were ana- 
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Klk 1  ATGGATGGAGGCAAAGACACTT  ACCTTGGAGAACACCATCACAGA  X04480  IGFI  CTACAAAAGCAGCCCGCTCTA  TCCTTCTGAGTCTTGGGCATGT  X81580  IGFBP2  GGAACATCTCTACTCCCTGCACAT  TTGTACCGGCCATGCTTGT  NM_010518  IGFBP5  GGTGTGTGGACAAGTACGGAATGA  ACGTTACTGCTGTCGAAGGCGT  X00525 Ribosomal 28S AGACCGTCGTGAGACAGGTTAGTT GCAGGATTACCATGGCAACAA lyzed in the uterus, vagina and mammary gland. The total normalized signals between controls and E 2 -exposed mice exhibited high correlations (R 2 =0.95-0.96) (Fig. 1 ). The total number of genes showing at least 2-fold expression change 6 hr after a single injection of E 2 was 656 in all samples ( Fig. 1 ). E 2 did not alter any gene expression more than 2-fold change in the mammary gland in the present study (data not shown). Genes showing organ-specific expression were 155 and 351 in the uterus and vagina, respectively (Fig. 1 ). Among them, 150 genes were regulated commonly in the uterus and vagina (Fig. 1) .
In the uterus, 228 genes were up-regulated and 77 genes were down-regulated by E 2 as compared to the controls (Fig  2) . In the vagina, 446 genes were up-regulated and 35 were down-regulated by E 2 . In the uterus, 63% of E 2 up-regulated genes were overlapped those in the vagina. E 2 down-regulated common genes in the uterus and vagina were only 6 (Fig. 2) . We further analyzed genes related to cell growth and organogenesis to find tissue-specific genes. E 2 -responsive genes related to development, cell growth and apoptosis in the uterus and vagina were listed in Table 2 .
Expression of Igf-1 family and Kallikrein 1 genes: Since clustering analysis revealed many E 2 -regulated genes, we compared expressions of Kallikrein 1 (Klk1) genes and Igf-1 family genes in each tissue using QRT-PCR.
In the controls, expression of Klk1 mRNA was similar between uterus and vagina, while those of Igf-1 and Igfbp5 were lower in the vagina than in the uterus (Fig. 3) . In the mammary gland, unlike the uterus and vagina, expressions of all mRNAs examined were very low or undetectable in the ovariectomized mice with or without E 2 . In the uterus and vagina, expression of Igf-1 mRNA was markedly increased by E 2 . However, expressions of Igfbp2 and Igfbp5 mRNAs were increased by E 2 in the vagina (Fig. 3) . Klk1 mRNAs was significantly increased as by E 2 in the vagina.
BrdU incorporation in the uterus, vagina and mammary gland, vagina 24 hr after E 2 injection: BrdU labeled cells were barely detected in epithelial cells of the uterus and mammary gland (0% and 0.05%) in the controls, as compared to those of the vagina (0.24%) in the controls (Fig. 4) . The BrdU labeling index in the epithelial cells of the uterus and vagina was significantly increased 24 hr after the E 2 injection as compared with each control. In the mammary gland, however, BrdU-positive cells were not evident in the epithelium 24 hr after the E 2 injection. The index was significantly increased by E 2 in the uterine stroma (Fig. 4) .
DISCUSSION
Estrogen regulates mitosis and morphological changes in female reproductive organs during proliferative events, such as estrous cycles, gestation and lactation. In order to understand the underlying mechanisms of estrogen functions in reproductive organs, detection of estrogen responsive genes in each reproductive organs are is essential. Effects of estrogen are different in each reproductive organ, therefore we investigated a global gene expression in uterus, vagina and mammary gland after a single injection of E 2 .
In the present study, BrdU labeled cells were remarkably increased in the uterine and vaginal epithelia, and in the uterine stroma after the E 2 injection, but not in any parts of the mammary gland. Gene expression in response to estrogen is different among these organs. Igf-1 is a key epithelial mitogen induced by estrogenic chemicals [28, 31] , whereas IGFBP prevents signal pathway by binding to Igf-1, and inhibits phosphorlylation of Insulin receptor substrate-1 (IRS-1), Phosphatidylinositol 3-kinase (PI3K), Protein kinase B (PKB) and Forkhead transcription factors (FKHRL1) [23] . Igfbp2 and Igfbp5 promote apoptosis in the prostate cancer cells and mammary gland cells [23, 26, 27, 29] . Hence, proliferations of uterine and vaginal cells was appear to be regulated by estrogen via Igf-1 and receptor complex, and its modulator. In the present study, estrogen increased Igf-1 mRNA and mitosis in the uterus and vagina. However, the Igf-1 modulators and Igfbp mRNAs were also increased in E 2 -exposed vagina. This may be accounted for by the suppression of stromal cell proliferation caused by increase of Igfbp mRNAs in the stroma rather than the epithelium. Up-regulation of Klk1 was reported by E 2 in the uterus [34] . Klk plays an important role for the release of bradykinin from kininogen, activation of growth factors and alteration of the extracellular matrix in the uterine epithelium [7] . Klk is regulated hormonally [7, 8] and the gene expression was found in human ovarian, prostate and breast cancer cells and in mouse vagina [15, 25, 37] . We found the up-regulation of Klk1 gene expression in the vagina by QRT-PCR. Thus, Klk1 may be related to epidermal proliferation and their expressions can be used for markers of acute response to estrogen in the uterus and vagina. We found that estrogen regulated genes were markedly limited in the mammary gland as compared to those in the uterus and vagina 6 hr after the E 2 exposure. Global gene expression in E 2 -exposed mammary gland has not been reported. Only gene expression in human breast cancer MCF-7 cells treated E 2 in vitro was reported [4, 10, 11] . MCF-7 cells treated with E 2 revealed the major down-regulation (70%) of gene expression including transcriptional repressor, antiproliferative and proapoptotic genes, such as Bcl-2, Cyclin G2 and TGF-β family [11] . Moreover, using the serial analysis of gene expression (SAGE) method, 3 upregulated genes were reported in MCF-7 cells 10 hr after E 2 treatment in vitro [4] . The genes reported as E 2 down-regulated genes in MCF-7 cells were not found in the mammary gland in the present study. MCF-7 cells are a single species of mammary cancer cells and show precise response of time-and dose-dependent proliferation to estrogen. Normal mammary gland may need longer than 6 hr to respond to E 2 in vivo. Mammary gland has various types of cells, such as epithelial cells stromal cells and adipocytes. Thus, we need further precise experiment to understand estrogen responsive genes in the mammary gland.
Although the mammary gland is known to be one of the target organs of estrogen, ER-α knockout (αERKO) mice showed proliferation and morphogenesis of the mammary gland in adulthood [24] . The mammary gland seems to be regulated by progesterone and prolactin rather than estrogen [5, 12, 15, 17, 24, 33] . The up-regulation of gene expression, such as IRS-1, Msx-2, C/EBPβ and Stat5, by progesterone was reported in human breast cancer cells [15] . Prolactin induced expression of Igf-2 mRNA in the developing mammary gland [13] . Thus, mammary gland is possibly regulated largely by progesterone and/or prolactin. This may account for no expression of estrogen responsive genes observed 6 hr after the E 2 exposure and absence of definite mitogenic response in the mammary gland of ovariectomized adult mice 24 hr after the E 2 exposure.
In conclusion, E 2 regulates expression of a number of genes in the vagina and uterus, but not in the mammary gland. Half of E 2 -regulated genes in the uterus were in common with the vagina including Kallikrein and Igf family genes. Differences in expression of these genes in response to E 2 may be leased on the tissue specificity to estrogen exposure. The candidate estrogen responsive genes in the uterus and vagina identified by profiling provide an important foundation to understand functional mechanisms of estrogen regulating morphogenesis and maintenance of the reproductive organ.
